secwatch.observer — SEC 8-K summary
======================================

Issuer:     Foghorn Therapeutics Inc. (FHTX)
CIK:        0001822462
Form:       8-K
Filed at:   2022-11-08T23:59:59+00:00
Accession:  0001628280-22-028753
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Foghorn reports Q3 2022 net loss $25.8M; FDA places FHD-286 AML/MDS trial on full clinical hold
--------------------------------------------------------------------------------

- Cash $373.5M as of Sep 30, 2022; runway into 2025.
- FDA full clinical hold on FHD-286 AML/MDS study due to fatal differentiation syndrome; hold to be resolved.
- FHD-286 mUM dose escalation continues; initial data expected H1 2023.
- FHD-609 shows BRD9 degradation in synovial sarcoma biopsies; efficacy/safety data expected 2023.
- New selective CBP degrader program disclosed; Merck collaboration triggered $5M milestone payment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1822462/000162828022028753/0001628280-22-028753-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1822462/000162828022028753/fhtx-20221108.htm
  HTML page:      https://secwatch.observer/filing/0001628280-22-028753

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer